Suppression of casein kinase 2 sensitizes tumor cells to antitumor TRAIL therapy by regulating the phosphorylation and localization of p65 in prostate cancer

Oncology Reports

Volumn 34, Issue 3, 2015, Pages 1599-1604

  Gang, Xiaokun ^a,c   Wang, Yao ^b,d   Wang, Yingdi ^e   Zhao, Yu ^c   Ding, Liya ^c   Zhao, Jingwen ^a,c   Sun, Lin ^a   Wang, Guixia ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c MAYO CLINIC   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e Jilin Provincial Hospital   (China)

Author keywords

Casein kinase 2; P65; Prostate cancer; TRAIL

Indexed keywords

4,5,6,7 TETRABROMOBENZOTRIAZOLE; CASEIN KINASE II; MESSENGER RNA; PROTEIN BCL XL; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE R; TNFSF10 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

APOPTOSIS; CASEIN KINASE II; CELL LINE, TUMOR; EIF-2 KINASE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NF-KAPPA B; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84937239366     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4123     Document Type: Article

References (32)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Allen JE and El-Deiry WS: Regulation of the human TRAIL gene. Cancer Biol Ther 13: 1143-1151, 2012.
3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
4. Morales JC, Ruiz-Magaia MJ and Ruiz-Ruiz C: Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: Role of NF-kappaB inhibition. Mol Immunol 44: 2587-2597, 2007.
5. Kim YS, Schwabe RF, Qian T, Lemasters JJ and Brenner DA: TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36: 1498-1508, 2002.
6. Keane MM, Rubinstein Y, Cuello M, Ettenberg SA, Banerjee P, Nau MM and Lipkowitz S: Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 64: 211-219, 2000.
7. Jani TS, DeVecchio J, Mazumdar T, Agyeman A and Houghton JA: Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285: 19162-19172, 2010.
8. Ozören N and El-Deiry WS: Defining characteristics of types I and II apoptotic cells in response to TRAIL. Neoplasia 4: 551-557, 2002.
9. Stuckey DW and Shah K: TRAIL on trial: Preclinical advances in cancer therapy. Trends Mol Med 19: 685-694, 2013.
10. Gonzalvez F and Ashkenazi A: New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29: 4752-4765, 2010.
11. Voelkel-Johnson C: TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol 8: 417-427, 2011.
12. Chen C, Edelstein LC and Gélinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20: 2687-2695, 2000.
13. Luo W, Yu WD, Ma Y, Chernov M, Trump DL and Johnson CS: Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Res 73: 2289-2297, 2013.
14. Agarwal M, Nitta RT and Li G: Casein kinase 2: A novel player in glioblastoma therapy and cancer stem cells. J Mol Genet Med 8: 8, 2013.
15. Wang G, Ahmad KA and Ahmed K: Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res 66: 2242-2249, 2006.
16. Orzechowska E, Kozłowska E, Staroń K and Trzcińska- Danielewicz J: Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability. Oncol Rep 27: 281-285, 2012.
17. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA and Huang H: Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 12: 1108-1114, 2010.
18. Silva L, Oh HS, Chang L, Yan Z, Triezenberg SJ and Knipe DM: Roles of the nuclear lamina in stable nuclear association and assembly of a herpesviral transactivator complex on viral immediate-early genes. MBio 3: e00300-e00311 2012.
19. Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, Wang F, Reindl KM, Wu E and Ma Q: Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling. BMC Cancer 14: 686, 2014.
20. Hu J, Nakano H, Sakurai H and Colburn NH: Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. Carcinogenesis 25: 1991-2003, 2004.
21. Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S and Aggarwal BB: Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood 113: 2003-2013, 2009.
22. Kim HR, Kim K, Lee KH, Kim SJ and Kim J: Inhibition of casein kinase 2 enhances the death ligand- and natural killer cell-induced hepatocellular carcinoma cell death. Clin Exp Immunol 152: 336-344, 2008.
23. Llobet D, Eritja N, Encinas M, Llecha N, Yeramian A, Pallares J, Sorolla A, Gonzalez-Tallada FJ, Matias-Guiu X and Dolcet X: CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 27: 2513-2524, 2008.
24. Hundsdörfer C, Hemmerling HJ, Hamberger J, Le Borgne M, Bednarski P, Götz C, Totzke F and Jose J: Novel indeno[1,2-b] indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines. Biochem Biophys Res Commun 424: 71-75, 2012.
25. Wang G, Ahmad KA, Unger G, Slaton JW and Ahmed K: CK2 signaling in androgen-dependent and -independent prostate cancer. J Cell Biochem 99: 382-391, 2006.
26. Tong L, Yuan Y and Wu S: Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers. Adv Drug Deliv Rev 81: 1-15, 2015.
27. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW and Matusik RJ: Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene: Sep 15, 2014 (Epub ahead of print). http://dx.doi.org/10.1038/onc.2014.302.
28. Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC and Sonenshein GE: Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res 65: 11375-11383, 2005.
29. Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A, Pizzi M, Cappellesso R, Zaffino F, Di Maggio SA, Cabrelle A, et al: Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS One 8: e75280, 2013.
30. Kim KJ, Cho KD, Jang KY, Kim HA, Kim HK, Lee HK and Im SY: Platelet-activating factor enhances tumour metastasis via the reactive oxygen species-dependent protein kinase casein kinase 2-mediated nuclear factor-κB activation. Immunology 143: 21-32, 2014.
31. Douillette A, Bibeau-Poirier A, Gravel SP, Clément JF, Chénard V, Moreau P and Servant MJ: The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IkappaB kinase complex. J Biol Chem 281: 13275-13284, 2006.
32. Gutierrez H, O'Keeffe GW, Gavaldà N, Gallagher D and Davies AM: Nuclear factor kappa B signaling either stimulates or inhibits neurite growth depending on the phosphorylation status of p65/RelA. J Neurosci 28: 8246-8256, 2008.